Neural fragility and neural excitability, as shown in the current study, are useful biological indices to quantify the functional consequences of Aβ and tau in AD patients and could help determine which pathological factor—Aβ or tau—more effectively contributes to clinical improvements when treated with anti-Aβ immunotherapies. The gene discussed is MAPT; the disease is Alzheimer disease.